$INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Healthcare
Sector
Biotechnology
Industry
Jennifer S. Buell
CEO
23
Employees
$9.74
Current Price
$58.21M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $22,051.76 | 1,500 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 6 | $27,477.66 | 2,000 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 6 | $27,477.66 | 2,000 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 6 | $27,477.66 | 2,000 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Ryan Barbara Director | Sale | 200 | $10.17 | $2,034.50 | View Details |
| Mar 10, 2026 | Ryan Barbara Director | Sale | 300 | $15.28 | $4,584.66 | View Details |
| Mar 10, 2026 | Ryan Barbara Director | Sale | 500 | $15.57 | $7,782.60 | View Details |
| Mar 10, 2026 | Ryan Barbara Director | Sale | 500 | $15.30 | $7,650.00 | View Details |
| Feb 27, 2026 | Ryan Barbara Director | Sale | 400 | $10.86 | $4,343.32 | View Details |
| Mar 2, 2026 | Ryan Barbara Director | Sale | 100 | $10.83 | $1,082.58 | View Details |
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.68
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.68
ActualN/A
Revenue
EstimatedN/A
ActualN/A